Matinas reports financial results for the three and six months ended June 30, 2024 and provides a business update. The Company will host a conference call and webcast today beginning at 4:30 p.m. ET. For dial-in and webcast details, please visit: https://bit.ly/46L9A0y
关于我们
Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.
- 网站
-
https://www.matinasbiopharma.com/
Matinas BioPharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Bedminster，New Jersey
- 类型
- 上市公司
- 创立
- 2011
地点
-
主要
获取路线
1545 Route 206, Suite 302
US，New Jersey，Bedminster，07921
Matinas BioPharma员工
动态
-
Matinas will host a conference call and webcast to discuss Q2 2024 financial results and provide a business update tomorrow, August 14th at 4:30 p.m. ET (1:30 p.m. PT). For details: https://bit.ly/46A3sIH
-
Matinas will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. ET (1:30 p.m. PT). For webcast details: https://bit.ly/3SGfhau
-
“We remain very excited by the consistently positive clinical impact of broad-spectrum, oral MAT2203,” said Theresa Matkovits, Ph.D., Chief Development Officer at Matinas. Learn about Matinas' Compassionate/ Expanded Use Access Program and plans to advance MAT2203 into a Phase 3 trial: https://bit.ly/3VEf1t3
-
Sharan Yadav, MD, Infectious Disease Fellow, comments on the successful treatment of a patient with limb-threatening Mucor infection in Matinas' oral MAT2203 Compassionate/Expanded Use Access Program: https://bit.ly/3VEf1t3
-
Matinas announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas’ Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow. For more: https://bit.ly/3VEf1t3
-
Tune-in today, June 18th at 4 p.m. ET for a fireside chat with antifungal expert Dr. David S. Perlin featuring MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. Register for the event: https://bit.ly/4b41m4v
-
Save the date: Matinas' MAT2203 will be featured in a fireside chat tomorrow, June 18th. The discussion with antifungal expert Dr. David S. Perlin will include a review of the antifungal treatment landscape, the advantages of MAT2203 versus IV-amphotericin B and the MAT2203 market opportunity. Register for the event here: https://bit.ly/4b41m4v
-
Matinas announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat on Tuesday, June 18th with David S. Perlin, PhD, a recognized expert in antifungals. The event is being sponsored by Alliance Global Partners (A.G.P.) and hosted by Scott Henry, A.G.P. Managing Director and Senior Research Analyst. For details: https://bit.ly/4ehynNb
-
Matinas announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston. For details: https://bit.ly/3V32sZi #TIDESUSA